KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Current Assets (2018 - 2025)

Castle Biosciences' Current Assets history spans 7 years, with the latest figure at $361.1 million for Q4 2025.

  • For Q4 2025, Current Assets changed 0.26% year-over-year to $361.1 million; the TTM value through Dec 2025 reached $361.1 million, changed 0.26%, while the annual FY2025 figure was $361.1 million, 0.26% changed from the prior year.
  • Current Assets for Q4 2025 was $361.1 million at Castle Biosciences, up from $357.6 million in the prior quarter.
  • Across five years, Current Assets topped out at $426.7 million in Q1 2021 and bottomed at $269.1 million in Q2 2023.
  • The 5-year median for Current Assets is $340.6 million (2022), against an average of $332.4 million.
  • The largest annual shift saw Current Assets skyrocketed 266.08% in 2021 before it fell 23.15% in 2022.
  • A 5-year view of Current Assets shows it stood at $353.7 million in 2021, then dropped by 17.37% to $292.3 million in 2022, then increased by 1.15% to $295.6 million in 2023, then rose by 21.82% to $360.2 million in 2024, then increased by 0.26% to $361.1 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Current Assets are $361.1 million (Q4 2025), $357.6 million (Q3 2025), and $348.7 million (Q2 2025).